Skip to main content

Grafa News and Videos — Page 1005

Grafa Headlines

Latest

Grafa

Verastem Oncology reports positive RAMP 205 data in front-line pancreatic cancer

Verastem Oncology (NASDAQ:VSTM) today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating its investigational combination regimen in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).

Read more: Verastem Oncology reports positive RAMP 205 data in front-line pancreatic cancer

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift